Profile View
Gilda Gali Hillman, Ph.D.
Biography
Director, Radiation/Gene Therapy/Soy Program
EDUCATION
1969 Baccalaureate, Lycee Paul Valerie, Paris, France
1973 B.Sc., Biology, Hebrew University, Jerusalem, Israel
1976 M.Sc., Virology, Hebrew University, Jerusalem, Israel
1983 Ph.D., Virology, Hebrew University, Jerusalem, Israel
RESEARCH TRAINING
1973
Research Assistant, Department of Pharmacology, the Hebrew University. Jerusalem, Israel. Radioimmunoassay for prolactin and HPL.
1973-1975
M.Sc. Student, Department of Virology, the Hebrew University, Jerusalem, Israel. Influence of the anti-cancer drugs, Vinblastine and Vincristine on the synthesis of DNA and ribosomal RNA.
1976
Research Associate, Department of Virology, the Hebrew University, Jerusalem, Israel. Investigation of the replication of RNA tumor viruses reverse transcription and its regulation. .
1977-1982
Graduate Student with Prof. Z. Zakay-Rones, Department of Virology, the Hebrew University, Jerusalem, Israel. Thesis: Effect and Mechanism of Action of Non-Oncogenic Viruses on Human Malignant Cells (Oncolysis) in vitro and in vivo.
1982-1985
Postdoctoral Associate, Department of Therapeutic Radiology and Laboratory of Medicine and Pathology, University of Minnesota, Minneapolis, MN. Destruction of human leukemia and lymphoma cells by immunotoxins in in vitro and in vivo systems.
1986-1990
Associate Researcher with Prof. Paul Sondel, Department of Human Oncology, CSC, University of Wisconsin, Madison, WI. Functional and phenotypic analysis of LAK cells generated in cancer patients by in vivo IL-2 therapy.
FACULTY APPOINTMENT
July 1998-present
Associate Professor, Department of Radiation Oncology, Wayne State University, Detroit, MI.
Aug 1996-June 1998
Associate Professor, Department of Urology, Wayne State University, Detroit, MI.
July 1990-July 1996
Assistant Professor, Department of Urology, Wayne State University, Detroit, MI.
HOSPITAL / PROFESSIONAL APPOINTMENTS
1990-present
Associate Member of the Immunology and Microbiology Department, Wayne State University, Detroit, MI
Director of Tumor Immunology Laboratory, Department of Urology, Wayne State University, Detroit, MI
Awards & Honors
Outstanding academic achievement prize from the Women's Academic Association of the Hebrew University, 1974
Post doctoral fellowship from Anna Fuller Fund (1982-1984)
Henry Bayles research fellowship from Israel Cancer Research Fund (1982-1983)
Jacob I. Schaffer Faculty Award for outstanding achievement and excellent Ph.D. Thesis, 1983
NCI-ACR travel award to attend First International Conference on Translational Research and Pre-Clinical Strategies in Radio-Oncology, Lugano, Switzerland, 2000.
Publications
ORIGINAL OBSERVATIONS IN REFEREED JOURNALS
1. Panet, G. Weil and R.R. Friis. Binding of Tryptophanyl-tRNA to the reverse transcriptase of replication defective avian sarcoma viruses. Journal of Virology 28: 434-443, 1978.
2. A. Morag, R. Levy, G. Weil and Z. Zakay-Rones. Clinical and serological response in humans following immunization with Gripax Influenza vaccine. Journal of Medical Virology 11: 67-75, 1983.
3. G. Weil-Hillman and Z. Zakay-Rones. Arrest of Daudi cell growth by inactive influenza virus in vitro. Scanning Electron Microscopy. IV: 1679-1686, 1985.
4. G. Weil-Hillman, H. Gamliel, A. Friedmann, and Z. Zakay-Rones. Visualization of the fate of inactive influenza viruses in Daudi cells by Electron Microscopy. Scanning Electron Microscopy. IV: 1687-1693, 1985.
5. G. Weil-Hillman and Z. Zakay-Rones. Inhibition of Daudi tumor formation by inactive influenza virus in a nude mouse model. The Cancer Journal 1: 208-213, 1987.
6. G. Weil-Hillman, R. Levi, and Z. Zakay-Rones. Increase in Concanavalin A cap formation on lymphoma cells following interaction with inactive influenza viruses. Acta Virologica 35:238-246, 1991.
7. G. Weil-Hillman, W. Runge, F.K. Jansen and D.A. Vallera. Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model. Cancer Research 45: 1328-1336, 1985.
8. G. Weil-Hillman, F.M. Uckun, J.M. Manske and D.A. Vallera. Combined immunochemotherapy of human solid tumors in nude mice. Cancer Research 47: 579-585, 1987.
9. J.A. Hank, P.C. Kohler, G. Weil-Hillman, N. Rosenthal, K.H. Moore, B. Storer, D. Minkoff, J. Bradshaw, R. Bechhofer and P.M. Sondel. In vivo induction of the lymphokine activated killer phenomenon: Interleukin-2 dependent human non-Major Histocompatibility Complex-restricted cytotoxicity generated in vivo during administration of human recombinant IL-2. Cancer Research 48: 1965-1971, 1988.
10. G. Weil-Hillman, J.A. Hank, N.S. Rosenthal, and P.M. Sondel. Transient decrease in IL-2 responsive lymphocytes 24 hours after initiation of continuous IL-2 infusion in cancer patients. J. Biol. Resp. Mod. 7: 424-437, 1988.
11. G. Weil-Hillman, P. Fisch, A.F. Prieve, J.A. Sosman, J.A. Hank and P.M. Sondel. Lymphokine-activated killer activity induced by in vivo Interleukin 2 therapy: Predominate role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens. Cancer Research 49: 3680-3688, 1989.
12. P. Fisch, G. Weil-Hillman, M. Uppenkamp, J.A. Hank, B.P. Chen, J.A. Sosman, A. Bridges, O.R. Colamonici and P.M. Sondel. Antigen-specific recognition of autologous leukemia cells and allogeneic class-I MHC antigens by IL-2-activated cytotoxic T cells from a patient with acute T-cell leukemia. Blood 74: 343-353, 1989.
13. J.A. Hank, G. Weil-Hillman, J.E. Surfus, J.A. Sosman and P.M. Sondel. Addition of Interleukin-2 in vitro augments detection of in vivo generated lymphokine-activated killer activity. Cancer. Immunol. Immunother. 31: 53-59, 1990.
14. D. Goldstein, J.A. Sosman, J.A. Hank, G. Weil-Hillman, K.H. Moore, A. Borchert, R. Bechhofer, B. Storer, P.C. Kohler, D. Levitt and P.M. Sondel. Repetitive weekly cycles of Interleukin 2: Effect of outpatient treatment with a lower dose of interleukin 2 on non-Major-Histocompatibility-Complex-restricted killer activity. Cancer Research 49: 6832-6839, 1989.
15. G. Weil-Hillman, S.D. Voss, P. Fisch, K. Schell, J.A. Hank, J.A. Sosman, K. Sugamara and P.M. Sondel. NK cells activated by IL-2 treatment in vivo respond to IL-2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype. Cancer Research 50: 2683-2691, 1990.
16. S.D. Voss, R.J. Robb, G. Weil-Hillman, J.A. Hank, K. Sugamara, M. Tsudo, P.M. Sondel. Increased expression of the IL-2 receptor B chain (p70) on CD56+ NK cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate-affinity IL-2 binding. J. Exp. Med. 172: 1101-1114, 1990.
17. M.R. Albertini, K.R. Oettel, G. Weil-Hillman, M. Lindstrom, K. Schell, J.A. Hank and P.M. Sondel. Limiting dilution analysis of lymphokine activated killer cell precursor frequencies in peripheral blood lymphocytes of cancer patients receiving IL-2 therapy. J. Biol. Resp. Mod. 9: 456-462, 1990.
18. G. Weil-Hillman, K. Schell, D.M. Segal, J.A. Hank, J.A. Sosman and P.M. Sondel. Activation of human T cells obtained pre and post IL-2 therapy by anti-CD3 monoclonal antibody plus IL-2: Implications for combined in vivo treatment. J. Immunotherapy. 10: 267-277, 1991.
19. E.J. Dybal, G.P. Haas, R.L.Maughan, S.Sud, J.E. Pontes and G.G. Hillman. Synergy of radiation therapy and immunotherapy in murine renal cell carcinoma. J. Urology. 148:1331-1337, 1992.
20. A. Chakrabarty, G.G. Hillman, R. L. Maughan, E.J. Dybal, D.W. Visscher, J.E. Pontes, and G.P. Haas. Immunotherapy and radiation therapy combined for the treatment of murine renal carcinoma. Surgical Forum. XLIII:758-760,1992.
21. N.I. Obiri, G.G. Hillman, G.P. Haas, S. Sud and R.K. Puri. Expression of high affinity interleukin-4 receptors on human renal carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. J. Clin. Invest. 91: 88-93, 1993.
22. G.P. Haas, B.G. Redman, V.K. Rao, E. Dybal, J.E. Pontes and G.G. Hillman. Immunotherapy of metastatic renal cell cancer: Effect on the primary tumor. J. Immunotherapy. 13:130-135, 1993.
23. G.G. Hillman, N. Roessler, R.S. Fulbright, J.E. Pontes and G.P. Haas. 51Cr release assay adapted to a 96-well format sample reading. Biotechniques. 15:744-749, 1993.
24. N. Roessler, G.P. Haas and G.G. Hillman. Spotting plates for counting 51Cr release cytotoxicity assays. Matrix Application Note. 1993.
25. G.G. Hillman, N. Roessler, R.S. Fulbright, J.E. Pontes and G.P. Haas. Application of the direct Beta counter Matrix 96 for cytotoxic assays: 51Cr retention assay assessed using a 96 format sample reading. Cancer. Immunol. Immunother. 36:351-356, 1993.
26. A. Chakrabarty, G.G. Hillman, R. L. Maughan, E. Ali, J.E. Pontes, and G.P. Haas. Radiation therapy enhances the therapeutic effect of immunotherapy on pulmonary metastases in a murine renal adenocarcinoma model. IN VIVO. 8:25-32, 1994.
27. G.G. Hillman, R.K. Puri, M.A. KuKuruga, J.E. Pontes and G.P. Haas. Growth and Major Histocompatibility Antigen Expression Regulation by Interleukin-4, Interferon gamma and Tumor Necrosis Factor on Human Renal Cell Carcinoma Tumor Cell Lines. Clinical and Experimental Immunology. 96:476-483, 1994.
28. G.G. Hillman, M.L. Wolf, E.J. Montecillo, E. Younes, E. Ali, J.E. Pontes, G.P. Haas. Expansion of Activated Lymphocytes Obtained from Renal Cell Carcinoma in a Hollow Fiber Bioreactor. Cell Transplantation. 3:263-271, 1994.
29. A. Chakrabarty, G.G. Hillman, R. L. Maughan, D. Visscher, E. Ali, J.E. Pontes, and G.P. Haas. Influence of Tumor Site on the Therapy of Murine Kidney Cancer. Anticancer Research. 14:373-378, 1994.
30. E. Younes, G.P. Haas, D. Visscher, J.E. Pontes, R.K. Puri and G.G. Hillman. Intralesional treatment of established murine primary renal tumor with interleukin-4: Localized effect on primary tumor with no impact on metastases. J. Urology. 153:490-493, 1995.
31. G.G. Hillman, E. Younes, D. Visscher, E. Ali, E.J. Montecillo, J.E. Pontes, G.P. Haas and R.K. Puri. Systemic treatment with interleukin-4 induces regression of pulmonary metastases in a murine renal cell carcinoma model. Cellular Immunology, 160:257-263, 1995.
32. E. Younes, G.P. Haas, B. Dezso, E. Ali, R. L. Maughan, E.J. Montecillo, J.E. Pontes, and G.G. Hillman. Radiation induced effects on murine kidney tumor cells: Role in the interaction of local irradiation and immunotherapy. J. Urology, 153:2029-2033, 1995.
33. E. Younes, G.P. Haas, B. Dezso, E. Ali, R. L. Maughan, M.A. KuKuruga, E.J. Montecillo, J.E. Pontes and G.G. Hillman. Local tumor irradiation augments the response to IL-2 therapy in a murine renal adenocarcinoma. Cellular Immunology, 165:243-251, 1995.
34. J.S. Lam, G.G. Hillman, E. Younes, E. Ali, R. L. Maughan, E.J. Montecillo, J.E. Pontes and G.P. Haas. Effect of Local Tumor Irradiation and IL-2 Therapy in Separate Murine Tumors. J. Immunotherapy, 18:28-34, 1995.
35. B. Dezso, G.P. Haas, F. Hamzavi, S. Kim, E.J. Montecillo, P.D. Benson, J.E. Pontes, R.L. Maughan, and G.G. Hillman. The Mechanism of Local Tumor Irradiation Combined With Interleukin 2 Therapy in Murine Renal Carcinoma: Histological Evaluation of Pulmonary Metastases. Clinical Cancer Research, 2:1543-1552, 1996.
36. A. Maini, G.G. Hillman, G.P. Haas, C.Y. Wang, E. Montecillo, F. Hamzavi, J.E. Pontes, P. Leland, I. Pastan, W. Debinski, and R.K. Puri. Interleukin-13 Receptors on Human Prostate Carcinoma Cell Lines Represent a Novel Target for a Chimeric Protein Composed of IL-13 and a Mutated Form of Pseudomonas Exotoxin. J. Urology, 158:948-953, 1997.
37. G.G. Hillman, E. Younes, D. Visscher, F. Hamzavi, S. Kim, J.S. Lam, E.J. Montecillo, E. Ali, J.E. Pontes, R.K. Puri and G.P. Haas. Inhibition of Murine Renal Carcinoma Pulmonary metastases by Systemic Administration of Interferon Gamma: Mechanism of Action and Potential for Combination with IL-4. Clinical Cancer Research, 3:1799-1806, 1997.
38. B. G. Redman, G.G. Hillman, L. Flaherty, J. Forman, B. Dezso and G.P. Haas. Phase II Trial of Sequential Radiation and Interleukin-2 in the Treatment of Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 4:283-286, 1998.
39. J.A. Triest, D. Grignon, M. L. Cher, S. V. Kocheril, E. J. Montecillo, B. Talati, S. Tekyi-Mensah, J.E. Pontes, and G.G. Hillman. Systemic Interleukin-2 Therapy for Human Prostate Tumors in a Nude Mouse Model. Clinical Cancer Research, 4:2009-2014, 1998.
40. D. Nie, G.G. Hillman, T. Geddes, K. Tang, C. Pierson, D.J. Grignon and K.V. Honn. Platelet-Type 12-Lipoxygenase in a Human Prostate Carcinoma Stimulates Angiogenesis and Tumor Growth. Cancer Research, 58:4047-4051, 1998.
41. N. Nishisaka, A. Maini, Y. Kinoshita, R. Yasumoto, R.F. Jones, P. Morse, G.G. Hillman, C.Y. Wang and G.P. Haas. Immunotherapy for Lung Metastases of Murine Renal Cell Carcinoma: Synergy between Radiation and Cytokine-Producing Tumor Vaccines. J. Immunotherapy. 22:308-314, 1999.
42. S. V. Kocheril, D. Grignon, C.Y. Wang, R. L. Maughan, E. J. Montecillo, B. Talati, S. Tekyi-Mensah, J.E. Pontes, and G.G. Hillman. Responsiveness of Human Prostate Carcinoma Bone Tumors to Interleukin-2 Therapy in a Mouse Xenograft Tumor Model. Cancer Detection and Prevention, 23: 408-416, 1999.
43. G.G. Hillman, R. L. Maughan, D. J. Grignon, M. Yudelev, J. Rubio, S. Tekyi-Mensah, A. Layer, M. Che and J. D. Forman. Neutron or Photon Irradiation for Prostate Tumors: Enhancement of Cytokine Therapy in a Metastatic Tumor Model. Clinical Cancer Research, 7: 136-144, 2001.
44. G.G. Hillman, J. D. Forman, O. Kucuk, M. Yudelev, R. L. Maughan, J. Rubio, A. Layer, S.Tekyi-Mensah, J. Abrams and F. H. Sarkar. Genistein Potentiates Radiation Effect on Prostate Carcinoma Cells. Clinical Cancer Research, 7: 382-390, 2001.
45. G. G. Hillman, R.L. Maughan, D.J.Grignon, M. Yudelev, M. Che, Y. Wang, A. Layer, J. L. Wright, and J.D. Forman. Sequential Photon or Neutron Radiation and Interleukin-2 for Prostate Carcinoma Bone Tumors in an Experimental Model. J. Immunotherapy, 24: 5, S10, 2001.
46. G. G. Hillman, R.L. Maughan, D.J.Grignon, M. Yudelev, M. Che, J. Abrams, Y. Wang, Layer, J. L. Wright, J. A. Rubio and J.D. Forman. Responsiveness of Experimental Prostate Carcinoma Bone Tumors to Neutron or Photon Radiation Combined with Cytokine Therapy. Int. J. Radiation Oncology Biology Physics. 56:1426-1437, 2003
47. G.G. Hillman, M. Xu, Y. Wang, J. L. Wright, X. Lu, L Kallinteris, S. Tekyi-Mensah, T. Thompson, M.S. Mitchell and J. D. Forman. Radiation Improves Intratumoral Gene Therapy for Induction of Cancer Vaccine in Murine Prostate Carcinoma. Human Gene Therapy, 14:763-775, 2003.
48. G.G. Hillman, N.L. Kallinteris, J.Li, Y. Wang, X. Lu, S. Wu, J. L. Wright, P. Slos, J.V. Gulfo, R.E. Humphreys, and M. Xu. Generating MHC Class II+/Ii- Phenotype After Adenoviral Delivery of both an Expressible Gene for MHC Class II Inducer and an Antisense Ii-RNA Construct. Gene Therapy, 10: 1512-1518, 2003.
49. X. Lu, N.L. Kallinteris, J. Li, S. Wu, Y. Li, Z.J. Li, G.G. Hillman, J.V. Gulfo, R.E. Humphreys, and M. Xu . Tumor immunotherapy by converting tumor cells to MHC Class II-positive, Ii protein-negative phenotype. Cancer Immunology Immunotherapy, 52:592-598, 2003.
50. D. Nie, J. Nemeth, Y. Qiao, A. Zacharek, L. Li, K. Hanna, K. Tang, G.G. Hillman, M.L. Cher, D.J. Grignon, and K.V. Honn. Increased Metastatic Potential in Human Prostate Carcinoma Cells by Overexpression of Arachidonate 12-Lipoxygenase. Clinical and Experimental Metastasis, 20: 657-663, 2003.
51. G.G. Hillman, P. Slos, Y. Wang, J. L. Wright, M. Yudelev, A. Layer, M. Che and J. D. Forman. Tumor Irradiation Followed by Intratumoral Cytokine Gene Therapy for Murine Renal Adenocarcinoma. Cancer Gene Therapy, 11: 61-72, 2004.
52. G.G. Hillman, Y. Wang, O. Kucuk, M. Che, D. R. Doerge, M. Yudelev, M.C. Joiner, B. Marples, J. D. Forman and F. H. Sarkar. Genistein Potentiates Inhibition of Tumor Growth by Radiation in a Prostate Cancer Orthotopic Model. Molecular Cancer Therapeutics, 3: 1271-1279, 2004.
53. Y. Wang, M. Xu, M. Che, E. Von Hofe, A. Abbas, N. L. Kallinteris, X. Lu, Z. J. Liss, J. D. Forman, and G.G. Hillman. Curative Anti-Tumor Immune Response Is Optimal with Tumor Irradiation Followed by Genetic Induction of MHC Class I and Class II Molecules and Suppression of Ii protein. Human Gene Therapy, 16:187-199, 2005.
54. O. Greco, M.C. Joiner, G.G. Hillman, A. D. Powell and S.D. Scott. Hypoxia and Radiation-Activated Cre/LoxP ‘Molecular Switch’ Vectors for Gene Therapy of Cancer. Gene Therapy, 1-10, 2005.
55. J.J. Raffoul, Y. Wang, O. Kucuk, J.D. Forman, F.H. Sarkar and G.G. Hillman. Genistein Inhibits Radiation-Induced Activation of NF-κB in Prostate Cancer Cells Promoting Apoptosis and G2/M Cell Cycle Arrest. BMC Cancer, 6:107, 2006.
56. Y. Wang, J.J. Raffoul , M. Che, Z.E. Knoll, A. Abbas , D. Doerge, O. Kucuk, F.H. Sarkar, G.G. Hillman. Prostate Cancer Treatment Is Enhanced by Genistein In Vitro and In Vivo in a Syngeneic Orthotopic Tumor Model. Radiation Research, 166: 73-80, 2006.
57. J.J. Raffoul, S. Banerjee, M. Che, Z.E. Knoll, D. Doerge, J. Abrams, O. Kucuk, F.H. Sarkar, and G.G. Hillman. Soy Isoflavones Enhance Radiotherapy in a Metastatic Prostate Cancer Model. International Journal Cancer, 120: 2491-2498, 2007.
58. J.J. Raffoul, S. Banerjee, V. Singh-Gupta, Z.E. Knoll, A. Fite, H. Zhang, J. Abrams, F.H. Sarkar, and G.G. Hillman. Downregulation of Apurinic/Apyrimidinic Endonuclease 1/Redox factor-1 (APE1/Ref-1) Expression by Soy Isoflavones Enhances Prostate Cancer Radiotherapy In Vitro and In Vivo. Cancer Research, 67: 2141-2149, 2007.
59. G.G. Hillman Y. Wang, M. Che, J.J. Raffoul, M. Yudelev, O. Kucuk and F.H. Sarkar. Progression of Renal Cell Carcinoma is Inhibited by Genistein and Radiation in an Orthotopic Model. BMC Cancer, 7:4, 2007.
60. V. Singh-Gupta, H. Zhang, S. Banerjee, J.J. Raffoul, F.H. Sarkar, and G.G. Hillman. Targeting Src, STAT3, HIF-1 and APE1/Ref-1 by Soy Isoflavones Contributes to Radiosensitization of Prostate Cancer. In preparation, 2008.
61. G.G. Hillman, V. Singh-Gupta, H. Zhang, A. Al-Bashir, Y. Katkuri, M. Li, C. K. Yunker, A. Patel, J. Abrams, E. M. Haacke. Dynamic Contrast Enhanced Magnetic Resonance Imaging of Vascular Changes Induced by Sunitinib in Papillary Renal Cell Carcinoma Xenograft Tumors. Submitted for Publication, 2009
62. G.G. Hillman, Y. Wang, M. Shaw, V. Singh-Gupta, H. Zhang, E. Von Hofe, M. Xu, and P. Slos. Strategies for Combining Tumor Irradiation and Gene Mediated Immunotherapy to Generate Potent Cancer Vaccines In Murine Prostate Carcinoma. In preparation, 2008.
63. V. Singh-Gupta, H. Zhang, F.H. Sarkar, and G.G. Hillman. Protective and Therapeutic Effect of Daidzein Isoflavonein Orthotopic Prostate Cancer Model. In preparation, 2008.
REVIEW ARTICLES
1. P.M. Sondel, J.A. Hank, P.C. Kohler, J.A. Sosman, G. Weil-Hillman and P. Fisch. The cellular immunotherapy of cancer: Current and potential uses of Interleukin-2. In: Critical Reviews in Oncology/Hematology (CRC Press) 9: 125-147, 1989.
2. S.D. Voss, G. Weil-Hillman, J.A. Hank, J. A. Sosman and P.M. Sondel. The clinical immunobiology of Interleukin-2: Potential modified uses for improved cancer treatment. Bull. N.Y. Acad. Med. 65: 93-110, 1989.
3. G.G. Hillman, G.P. Haas, W. Wahl and D.M. Callewaert. Adoptive immunotherapy of cancer: Biological Response Modifiers and cytotoxic cell therapy. Biotherapy. 5: 119-129, 1992.
4. G.G. Hillman, M.J. Terrier-Lacombe, J. Kattan and J.P. Droz. Biopathology of human renal cancer. La Revue du Praticien. (France) 42: 1205-1210, 1992.
5. G.P. Haas, G.G. Hillman, B.G. Redman, J.E. Pontes. Immunotherapy of renal cell carcinoma. CA-A Cancer Journal for Clinicians. 43:177-187, 1993.
6. G.G. Hillman, J.P. Droz and G.P. Haas. Experimental Animal Models for the Study of Therapeutic Approaches in Renal Cell Carcinoma. IN VIVO. 8:77-80, 1994.
7. S. Kim, G.P. Haas and G.G. Hillman. Development of Immunotherapy for the Treatment of Malignancies Refractory to Conventional Therapies. Cytokines and Molecular Therapy. 2:13-19, 1996.
8. G.P. Haas and G.G. Hillman. Update on the Role of Immunotherapy in the Management of Kidney Cancer. Cancer Control. 3:66-71, 1996.
9. K.A. Hanash, J.W. Aquilina, D.M. Barrett, M.L. Blute, A.T. Cockett, F.A. Corica, G.G. Hillman, B. Zbar, Z. Zhuang. Clinical Research Priorities in Renal Cell Carcinoma. Cancer, 80: 999-1001, 1997.
10. G.G. Hillman, J.A. Triest, M.L. Cher, S. V. Kocheril and B .R. Talati. Prospects of Immunotherapy for the Treatment of Prostate Carcinoma-A Review. Cancer Detection and Prevention, 23:333-342, 1999.
11. G.G. Hillman, Kallinteris N.L., Lu X., Wang Y., Wright J.L., Li Y, Wu S, Forman J.D., Gulfo J.V., Humphreys.R.E., and Xu M. Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing and immuno-consolidation. Cancer Treatment Reviews. 30: 281-290, 2004.
12. M. Xu, X. Lu, N. Kallinteris, Y. Wang, S. Wu, E. von Hofe, J. V. Gulfo, R. E. Humphreys and G. G. Hillman. Immunotherapy of cancer by antisense inhibition of Ii protein, an immunoregulator of antigen selection by MHC class II molecules. Current Opinion in Molecular Therapeutics. 6: 160-165, 2004.
13. R. E. Humphreys, G. G. Hillman, E. von Hofe, M. Xu. Forcing Tumor Cells to Present Their Own Tumor Antigens to the Immune System: A Necessary Design for an Efficient Tumor Immunotherapy. Cellular & Molecular Immunology. 1:180-185, 2004.
14. J.J. Raffoul, F.H. Sarkar, and G.G. Hillman. Radiosensitization of Prostate Cancer by Soy Isoflavones. Invited Review Article. Current Cancer Drug Targets, 7:759-765, 2007.
BOOKS AND CHAPTERS
1. P.M. Sondel, J.A. Hank, J.A. Sosman, P.C. Kohler, B.P. Chen, P. Fisch, V. Lam, R. Mandell, G. Weil-Hillman and S. Voss. Perspectives for cellular immunotherapy of cancer: Building upon regimens using tolerable doses of Interleukin-2 (IL-2). In: Human Tumor Antigens and Specific Tumor Therapy. Evans, G., Golde, D., Groopman, J. (eds), Alan R. Liss Press, NY, p163-174, 1989.
2. P.M. Sondel, J.A. Hank, G. Weil-Hillman, P. Fisch, M.R. Albertini, S.D. Voss and J.A. Sosman. The immunotherapy of cancer: Prospects for more specific antitumor efficacy. In: Cellular Immunology and Immunotherapy of Cancer. Lotze, M.T., Finn, O. (eds), Alan R. Liss Press, NY. pp 413-420, 1990.
3. G.G. Hillman, S.Sud, E.J. Dybal, J.E. Pontes and G.P. Haas. Combinations of lymphocyte activating agents for expansion of tumor infiltrating lymphocytes from renal cell carcinoma. In: Goldstein, A.L. and Garaci, E. (eds). Combination Therapies: Biological Response Modifiers in the Treatment of Cancer and Infectious diseases. Plenum Press,NY. pp 39-48, 1992.
4. G.G. Hillman and G.P. Haas. Role of Cytokines in Lymphocyte Functions. In: Aggarwal, B.B. and Puri, R.K. (eds). Human Cytokines: Their Role in Disease and Therapy. Blackwell Science, pp. 37-54, 1995.
5. G.G. Hillman. Experimental Animal Models for Renal Cell Carcinoma. In: Teicher, BA (eds). Tumor Models in Cancer Research. Humana Press, Inc., pp 493-505, 2002.
6. G.G. Hillman and F. H. Sarkar. Radiosensitization of Cancer Cells by Herbal Compounds: Role of Soy Isoflavones in Inhibition of Radiation-Induced Activation of Cell Survival Pathways. In: RK Sharma and R Arora (eds). Herbal Drugs: “A Twenty First Century Perspective”. Jaypee Brothers Medical Publishers Pvt. Ltd. Invited book chapter, In press 2009.